Tissue | Expression Dynamics | Abbreviation |
Breast | | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0008380112 | Skin | cSCC | RNA splicing | 263/4864 | 434/18723 | 2.45e-53 | 5.13e-50 | 263 |
GO:0000375112 | Skin | cSCC | RNA splicing, via transesterification reactions | 201/4864 | 324/18723 | 4.07e-43 | 5.10e-40 | 201 |
GO:0000377112 | Skin | cSCC | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 197/4864 | 320/18723 | 1.45e-41 | 1.14e-38 | 197 |
GO:0000398112 | Skin | cSCC | mRNA splicing, via spliceosome | 197/4864 | 320/18723 | 1.45e-41 | 1.14e-38 | 197 |
GO:000170124 | Skin | cSCC | in utero embryonic development | 150/4864 | 367/18723 | 2.47e-10 | 1.04e-08 | 150 |
GO:000182413 | Skin | cSCC | blastocyst development | 53/4864 | 106/18723 | 9.74e-08 | 2.32e-06 | 53 |
GO:000182512 | Skin | cSCC | blastocyst formation | 21/4864 | 38/18723 | 1.17e-04 | 1.08e-03 | 21 |
GO:00083806 | Stomach | CAG with IM | RNA splicing | 39/1050 | 434/18723 | 2.55e-03 | 2.49e-02 | 39 |
GO:00003776 | Stomach | CAG with IM | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 30/1050 | 320/18723 | 4.15e-03 | 3.56e-02 | 30 |
GO:00003986 | Stomach | CAG with IM | mRNA splicing, via spliceosome | 30/1050 | 320/18723 | 4.15e-03 | 3.56e-02 | 30 |
GO:00003756 | Stomach | CAG with IM | RNA splicing, via transesterification reactions | 30/1050 | 324/18723 | 4.95e-03 | 4.01e-02 | 30 |
GO:000838011 | Stomach | CSG | RNA splicing | 40/1034 | 434/18723 | 1.07e-03 | 1.35e-02 | 40 |
GO:000037711 | Stomach | CSG | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 31/1034 | 320/18723 | 1.74e-03 | 1.89e-02 | 31 |
GO:000039811 | Stomach | CSG | mRNA splicing, via spliceosome | 31/1034 | 320/18723 | 1.74e-03 | 1.89e-02 | 31 |
GO:000037511 | Stomach | CSG | RNA splicing, via transesterification reactions | 31/1034 | 324/18723 | 2.11e-03 | 2.17e-02 | 31 |
GO:000838021 | Stomach | CAG | RNA splicing | 32/552 | 434/18723 | 2.08e-06 | 1.16e-04 | 32 |
GO:000037721 | Stomach | CAG | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 24/552 | 320/18723 | 2.97e-05 | 1.02e-03 | 24 |
GO:000039821 | Stomach | CAG | mRNA splicing, via spliceosome | 24/552 | 320/18723 | 2.97e-05 | 1.02e-03 | 24 |
GO:000037521 | Stomach | CAG | RNA splicing, via transesterification reactions | 24/552 | 324/18723 | 3.62e-05 | 1.18e-03 | 24 |
GO:000838031 | Stomach | WIM | RNA splicing | 23/426 | 434/18723 | 1.66e-04 | 4.08e-03 | 23 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SF3B6 | SNV | Missense_Mutation | novel | c.109N>C | p.Asp37His | p.D37H | Q9Y3B4 | protein_coding | deleterious(0) | probably_damaging(0.944) | TCGA-AC-A3W6-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
SF3B6 | SNV | Missense_Mutation | novel | c.139C>A | p.Gln47Lys | p.Q47K | Q9Y3B4 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-B6-A0IM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SF3B6 | insertion | Nonsense_Mutation | novel | c.217_218insGCGTGAACCCCAGGGGGTGGAGCCTGCAGTGAGCCAAGAT | p.Ala73GlyfsTer11 | p.A73Gfs*11 | Q9Y3B4 | protein_coding | | | TCGA-A2-A0CP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
SF3B6 | insertion | In_Frame_Ins | novel | c.152_153insTCAAGCTGACTGTCACATCAGGAATACTAA | p.Gly51_Asn52insGlnAlaAspCysHisIleArgAsnThrLys | p.G51_N52insQADCHIRNTK | Q9Y3B4 | protein_coding | | | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
SF3B6 | SNV | Missense_Mutation | | c.13N>T | p.Ala5Ser | p.A5S | Q9Y3B4 | protein_coding | tolerated(0.41) | benign(0.001) | TCGA-CM-4743-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | capecitabine | SD |
SF3B6 | SNV | Missense_Mutation | novel | c.254N>T | p.Arg85Ile | p.R85I | Q9Y3B4 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
SF3B6 | SNV | Missense_Mutation | novel | c.235G>A | p.Gly79Arg | p.G79R | Q9Y3B4 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AX-A0J1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SF3B6 | SNV | Missense_Mutation | novel | c.161C>A | p.Pro54His | p.P54H | Q9Y3B4 | protein_coding | deleterious(0.03) | possibly_damaging(0.784) | TCGA-77-6845-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
SF3B6 | SNV | Missense_Mutation | novel | c.304N>A | p.Asp102Asn | p.D102N | Q9Y3B4 | protein_coding | tolerated(0.1) | benign(0.012) | TCGA-CN-6992-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | cisplatin | SD |
SF3B6 | insertion | Frame_Shift_Ins | novel | c.69_70insTA | p.Arg24Ter | p.R24* | Q9Y3B4 | protein_coding | | | TCGA-HD-A633-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |